AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|
24.3 C
New York
Saturday, September 12, 2026

Tag: options

ATN Night Vision Scopes Revolutionize Late-Night Hog Hunting for Serious Hunters

DORAL, Fla., June 21, 2025 (GLOBE NEWSWIRE) -- Wild hog hunting after dark presents a unique challenge even for the most seasoned sportsmen. Nocturnal and highly elusive, feral hogs demand precision, stealth, and top-tier equipment. That’s why hunters nationwide are turning to ATN, a global leader in digital and thermal optics, to gain the upper hand during late-night hunts.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

$255 Payday Loans Online Same Day No Credit Check Bad Credit Launched by Viva Payday Loans

Viva Payday Loans now offers $255 payday loans online same day with optional no credit check, delivering fast, transparent emergency cash support.

Analyzing Annuities’ Reputation: Evaluating Their Role in Strategic Financial Planning

Running out of money in retirement is a significant concern among investors, often surpassing even the fear of death. While maximizing contributions to an...

The China Fund, Inc. Announces Board Approval of Plan of Liquidation

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- The China Fund, Inc. (NYSE: CHN) (the “Fund”) announced today that its Board of Directors (the “Board”) has approved a plan of liquidation and dissolution (the “Plan”) for the Fund. The Plan will be submitted to Fund stockholders for approval at a Special Meeting. The date of the Special Meeting and more detailed information about the proposed liquidation and Plan will be set forth in a proxy statement to be mailed to the Fund’s stockholders in the near future. The Board recommends that the Fund’s stockholders vote for the liquidation of the Fund at the Special Meeting.

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

Treatment.com AI Grants Stock Option and RSUs

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) announces that it has granted 799,920 restricted share units (“RSUs”) and 162,480 stock options (“Options”) to officers, directors, consultants and employees of the Company.

XRP Holds the $2 Support Level, PFMCrypto Launches Yield-Driven XRP Mining Strategy

New XRP Cloud Mining Service Offers Passive Income and Stability Amid Market Volatility, Aiming to Restore Investor Confidence with Daily Returns

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).

CDT Environmental Technology Announces Receipt of Notification Letter from Nasdaq

SHENZHEN, China, June 20, 2025 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ:CDTG) (“CDT” or the “Company”), a leading provider of waste treatment systems and services throughout China, today announced that it received a notification letter, dated June 18, 2025 (the “Notification Letter”), from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as the Company’s closing bid price per ordinary share, par value US$0.0025 per share, was below US$1.00 for a period of 30 consecutive business days. The Notification Letter does not result in the immediate delisting of the Company’s securities.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOptions